Article
Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.
Oncotarget - 13 Dec 2016
Thiagarajan Praveena S, Wu Xiaoliang, Zhang Wei, Shi Ivy, Bagai Rakesh, Leahy Patrick, Feng Yan, Veigl Martina, Lindner Daniel, Danielpour David, Yin Lihong, Rosell Rafael, Bivona Trever G, Zhang Zhenfeng, Ma Patrick C
Abstract excerpt
The impact of EGFR-mutant NSCLC precision therapy is limited by acquired resistance despite initial excellent response. Classic studies of EGFR-mutant clinical resistance to precision therapy were based on tumor rebiopsies late during clinical tumor progression on therapy. Here, we characterized a novel non-mutational early adaptive drug-escape in EGFR-mutant lung tumor cells only days after therapy initiation,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.